Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes Obesity and Metabolism 2026 Open access

Read full text
Authors: Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa
DOI: 10.1111/dom.70550
Cited by: 3
References: 19

Abstract

AIMS: Despite the established efficacy of tirzepatide in randomised controlled trials, real-world effectiveness data in Japanese patients remain limited. This study evaluated the real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks. MATERIALS AND METHODS: This multi-site retrospective cohort study analysed 203 Japanese patients with type 2 diabetes who initiated tirzepatide at three outpatient clinics between July 2023 and August 2024. The primary endpoint was HbA1c change at 52 weeks. Subgroup analyses were performed on 22 predefined patient characteristics. RESULTS: . Most patients (82.3%) had prior antidiabetic therapy, including insulin (30.0%). The overall mean HbA1c reduction was -0.91% (95% confidence interval: -1.08 to -0.74, p < 0.001), with 61.2% achieving

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Diabetes Management and Research

Publication details

Journal / source
Diabetes Obesity and Metabolism
Publisher
Wiley
Volume
28
Issue
5
Pages
3703–3715
Publication date
12 February 2026
Language
EN